You are here

Application for Fabry Disease Treatment Pulled From FDA Review

The drug, Replagal, is an enzyme replacement therapy for the disease, which causes fat to build up in the body.

Shire had filed in November for FDA approval for Replagal, "in anticipation of a quick review process," the company said.

Shire has been permitted to supply the drug to the U.S. market after manufacturing problems in 2009 led to short supplies of rival drug Fabrazyme, which is made by Genzyme, now owned by Sanofi SA. Replagal has been on the market in Europe since 2001.

The FDA said Shire has also decided to end that treatment program over the next few months, and the drug will no longer be available to U.S. patients.

Read the full article on Reuters

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs